Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
Public ClinicalTrials.gov record NCT00153101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint. Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.
Study identification
- NCT ID
- NCT00153101
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 31,546 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2001 (Type not available)
- Primary completion
- Jun 2008 (Actual)
- Completion
- Not listed
- Last update posted
- May 20, 2014
Started 2001
United States locations
- U.S. sites
- 100
- U.S. states
- 33
- U.S. cities
- 87
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 502.373.0256 Boehringer Ingelheim Investigational Site | Athens | Alabama | — | — |
| 502.373.0251 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 502.373.0182 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 502.373.0188 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 502.373.0189 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 502.373.0177 Boehringer Ingelheim Investigational Site | Tuscon | Arizona | — | — |
| 502.373.0209 Boehringer Ingelheim Investigational Site | Bentonville | Arkansas | — | — |
| 502.373.0173 Boehringer Ingelheim Investigational Site | Concord | California | — | — |
| 502.373.0266 Boehringer Ingelheim Investigational Site | Harbor City | California | — | — |
| 502.373.0283 Boehringer Ingelheim Investigational Site | Loma Linda | California | — | — |
| 502.373.0180 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 502.373.0175 Boehringer Ingelheim Investigational Site | Sacramento | California | — | — |
| 502.373.0165 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 502.373.0228 Boehringer Ingelheim Investigational Site | San Leandro | California | — | — |
| 502.373.0205 Boehringer Ingelheim Investigational Site | Sylmar | California | — | — |
| 502.373.0277 Boehringer Ingelheim Investigational Site | West Hills | California | — | — |
| 502.373.0226 Boehringer Ingelheim Investigational Site | Bridgeport | Connecticut | — | — |
| 502.373.0174 Boehringer Ingelheim Investigational Site | Farmington | Connecticut | — | — |
| 502.373.0258 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 502.373.0179 Boehringer Ingelheim Investigational Site | Gainesville | Florida | — | — |
| 502.373.0183 Boehringer Ingelheim Investigational Site | Palm Harbor | Florida | — | — |
| 502.373.0240 Boehringer Ingelheim Investigational Site | Panama City | Florida | — | — |
| 502.373.0171 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 502.373.0282 Boehringer Ingelheim Investigational Site | Vero Beach | Florida | — | — |
| 502.373.0214 Boehringer Ingelheim Investigational Site | Weston | Florida | — | — |
| 502.373.0161 Boehringer Ingelheim Investigational Site | Augusta | Georgia | — | — |
| 502.373.0193 Boehringer Ingelheim Investigational Site | Augusta | Georgia | — | — |
| 502.373.0201 Boehringer Ingelheim Investigational Site | Augusta | Georgia | — | — |
| 502.373.0223 Boehringer Ingelheim Investigational Site | Conyers | Georgia | — | — |
| 502.373.0268 Boehringer Ingelheim Investigational Site | Sandersville | Georgia | — | — |
| 502.373.0245 Boehringer Ingelheim Investigational Site | Savannah | Georgia | — | — |
| 502.373.0199 Boehringer Ingelheim Investigational Site | Tucker | Georgia | — | — |
| 502.373.0162 Boehringer Ingelheim Investigational Site | Valdosta | Georgia | — | — |
| 502.373.0203 Boehringer Ingelheim Investigational Site | Pocatello | Idaho | — | — |
| 502.373.0244 Boehringer Ingelheim Investigational Site | Burbank | Illinois | — | — |
| 502.373.0272 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 502.373.0217 Boehringer Ingelheim Investigational Site | Olympia Fields | Illinois | — | — |
| 502.373.0270 Boehringer Ingelheim Investigational Site | Des Moines | Iowa | — | — |
| 502.373.0167 Boehringer Ingelheim Investigational Site | Monroe | Louisiana | — | — |
| 502.373.0158 Boehringer Ingelheim Investigational Site | Shreveport | Louisiana | — | — |
| 502.373.0247 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 502.373.0284 Boehringer Ingelheim Investigational Site | Boston | Massachusetts | — | — |
| 502.373.0229 Boehringer Ingelheim Investigational Site | Springfield | Massachusetts | — | — |
| 502.373.0237 Boehringer Ingelheim Investigational Site | Wyandotte | Michigan | — | — |
| 502.373.0208 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 502.373.0232 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 502.373.0231 Boehringer Ingelheim Investigational Site | Saint Paul | Minnesota | — | — |
| 502.373.0181 Boehringer Ingelheim Investigational Site | Biloxi | Mississippi | — | — |
| 502.373.0185 Boehringer Ingelheim Investigational Site | Cleveland | Mississippi | — | — |
| 502.373.0254 Boehringer Ingelheim Investigational Site | Jackson | Mississippi | — | — |
| 502.373.0195 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 502.373.0207 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 502.373.0239 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 502.373.0279 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 502.373.0169 Boehringer Ingelheim Investigational Site | North Las Vegas | Nevada | — | — |
| 502.373.0157 Boehringer Ingelheim Investigational Site | Camden | New Jersey | — | — |
| 502.373.0202 Boehringer Ingelheim Investigational Site | East Orange | New Jersey | — | — |
| 502.373.0191 Boehringer Ingelheim Investigational Site | Newark | New Jersey | — | — |
| 502.373.0271 Boehringer Ingelheim Investigational Site | Westwood | New Jersey | — | — |
| 502.373.0213 Boehringer Ingelheim Investigational Site | Brooklyn | New York | — | — |
| 502.373.0230 Boehringer Ingelheim Investigational Site | Buffalo | New York | — | — |
| 502.373.0288 Boehringer Ingelheim Investigational Site | Kingston | New York | — | — |
| 502.373.0238 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 502.373.0252 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 502.373.0286 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 502.373.0166 Boehringer Ingelheim Investigational Site | Northport | New York | — | — |
| 502.373.0156 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 502.373.0264 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 502.373.0227 Boehringer Ingelheim Investigational Site | Scarsdale | New York | — | — |
| 502.373.0150 Boehringer Ingelheim Investigational Site | The Bronx | New York | — | — |
| 502.373.0163 Boehringer Ingelheim Investigational Site | Westfield | New York | — | — |
| 502.373.0241 Boehringer Ingelheim Investigational Site | Williamsville | New York | — | — |
| 502.373.0273 Boehringer Ingelheim Investigational Site | Durham | North Carolina | — | — |
| 502.373.0261 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 502.373.0222 Boehringer Ingelheim Investigational Site | Fargo | North Dakota | — | — |
| 502.373.0155 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 502.373.0164 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 502.373.0168 Boehringer Ingelheim Investigational Site | Dayton | Ohio | — | — |
| 502.373.0159 Boehringer Ingelheim Investigational Site | Mansfield | Ohio | — | — |
| 502.373.0178 Boehringer Ingelheim Investigational Site | Oklahoma City | Ohio | — | — |
| 502.373.0259 Boehringer Ingelheim Investigational Site | Guthrie | Oklahoma | — | — |
| 502.373.0154 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 502.373.0152 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 502.373.0243 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 502.373.0265 Boehringer Ingelheim Investigational Site | Erie | Pennsylvania | — | — |
| 502.373.0153 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 502.373.0274 Boehringer Ingelheim Investigational Site | Sellersville | Pennsylvania | — | — |
| 502.373.0184 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 502.373.0248 Boehringer Ingelheim Investigational Site | Columbia | South Carolina | — | — |
| 502.373.0172 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 502.373.0187 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 502.373.0219 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 502.373.0275 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 502.373.0221 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 502.373.0206 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 502.373.0234 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 502.373.0280 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 502.373.0249 Boehringer Ingelheim Investigational Site | Burke | Virginia | — | — |
| 502.373.0281 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
| 502.373.0212 Boehringer Ingelheim Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 632 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00153101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2014 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00153101 live on ClinicalTrials.gov.